The U.S. baby infant formula market size was valued at $3,962.7 million in 2022 and is projected to reach $6,973.7 million by 2032, registering a CAGR of 5.7% from 2023 to 2032.

Infant formula serves as an ideal alternative suitable for infant consumption, which mimics the nutritional composition of breast milk as closely as possible. Although physicians recommend breast milk for optimal infant nutrition, it may not always be possible, suitable, or solely adequate. Enspire infant formula and toddler milk and Similac infant formula and toddler milk are infant formulas available for healthy, full-term infants who are not breastfed or partially breastfed.

The growth of the U.S. infant formula market is majorly driven by surge in female labor force participation. For instance, according to the United States Bureau of Statistics, the percentage of working women in the U.S. increased to 56.8% in 2022. Majority of working moms return to work soon after giving birth. As a result, breastfeeding is not always practical for working women owing to time constraints and inconvenience. In such cases, infant formula serves as an ideal choice for working women as it meets both the need for appropriate, nutritious meals for their newborns and their need for convenience.

The COVID-19 pandemic affected farmers and employees as carrying out operations was tough due to stringent lockdown rules initiated by the government. The pandemic has increased volatility and uncertainty for dairy companies as production was getting disrupted due to a lack of resources. The prices were fluctuating, due to the lower availability of milk in the market, which impacted on the overall price of the finished product.

A dip in the quality of raw materials was arising as farmers were trying to increase the volume of products to meet the demand from the baby food companies. Furthermore, the rise in transportation costs resulted in regular delays in product distribution across the U.S. In the current scenario, the vaccination drive and decline in COVID-19 cases around the globe have helped to normalize the situation. Governments have lifted the lockdown which has eased the difficulties in the supply chain.

Infant formula producers have evaluated several ingredients as a part of their continuous efforts to verify the nourishing and functional properties of human milk. Hence, many key players have set up extensive R&D to determine new ingredients. Consequently, to augment the health of infants, prebiotics, and probiotics are introduced in baby infant formula. The number of infant formulas manufactured using these elements has witnessed gradual growth. Prebiotics and probiotics that are categorized as GRAS (generally regarded as safe) by the FDA are now being promoted as an ingredient in commercial infant formulas.

This can be regarded as an U.S. baby infant formula market opportunities by the manufacturers to boost their product sales and gain an edge in the U.S. baby infant formula market in the near future. Some of the brands that have introduced their products in the market are as follows Hipp Dutch Stage 1 (0-6 Months) Organic Combiotic Infant Milk Formula, Kendamil Stage 1 (0-6 Months) Organic Baby Formula: (prebiotics), Earth’s Best Organic Toddler (prebiotics), Earth’s Best Organic Dairy (prebiotics) by The Hain Celestial, and Similac Probiotic Tri-Blend Supplement Powder.

However, infant formula is a highly susceptible food product to contamination/adulteration, which hampers the U.S. baby infant formula market growth. In the past, infant formula products were occasionally found to be contaminated with salmonella and E. coli. Although they are uncommon, these events can cause infants to suffer or even die. Some newborns may be allergic to the components in baby formula, such as soy or cow milk protein.

Hives, vomiting, diarrhea, and rashes are some of the symptoms prevalent among infants. Furthermore, certain parents are concerned that formula does not provide as much nutrition as breast milk or that it may contain nutrient imbalances that are harmful to their child's health. According to several studies, formula-fed infants are more likely to acquire health problems such as obesity, diabetes, and allergy as they grow. As a result, worries about the safety of newborn infant formula function as a key impediment to market expansion.

On the contrary, infant formula producers have evaluated several ingredients as a part of their continuous efforts to verify nourishing and functional properties of human milk. Hence, many key players have set up extensive R&D to determine new ingredients. Consequently, for proper development of infants, prebiotics and probiotics are introduced in baby infant formula. The number of infant formulas manufactured using these elements has witnessed gradual growth. Prebiotics and probiotics that are categorized as GRAS (generally regarded as safe) by the FDA are now being promoted as ingredients in commercial infant formulas.

This can be regarded as an opportunity by the manufacturers to boost their product sales and gain an edge in the U.S. baby infant formula market in the near future. Some of the brands that have introduced their products in the market are Hipp Dutch Stage 1 (0-6 Months) Organic Combiotic Infant Milk Formula, Kendamil Stage 1 (0-6 Months) Organic Baby Formula: (prebiotics), Earth’s Best Organic Toddler (prebiotics), Earth’s Best Organic Dairy (prebiotics) by The Hain Celestial, and Similac Probiotic Tri-Blend Supplement Powder.

The U.S. baby infant formula market is segmented into type, ingredient, distribution channel, and source. Depending on type, the market is segregated into infant milk, follow-on-milk, specialty baby milk, and growing-up milk. On the basis of ingredient, it is fragmented into carbohydrate, fat, protein, minerals, vitamins, and others. By distribution channel, it is categorized into hypermarkets, supermarkets, pharmacy/medical stores, specialty stores, hard discounter stores, and others. By source, it is classified into regular, organic, milk with HMO, goat milk, plant-based formula, and others.

According to the U.S. baby infant formula market analysis, on the basis of product type, the infant milk segment dominated the market in 2022 and is expected to dominate the market during the forecast period. Infant milk is specially designed to meet the growing needs of babies under six months of age, who are not breastfed or partially breastfed. The lack of acceptable alternatives—as only breast milk is a viable substitute—for infant milk is expected to drive the growth of the market. The composition of infant milk includes vitamins, minerals, prebiotics, and higher levels of iron than other formulas to compensate for nutritional deficiencies, which may occur in the transition phase of infant nutrition. In addition, it is enriched with vitamin D and calcium for normal growth and development of bones.

[PRODUCTTYPEGRAPH]

According to the U.S. baby infant formula market trends, on the basis of the ingredients, the carbohydrate segment dominated the market in 2022 and is expected to maintain its dominance during the forecast period. Carbohydrates are an important source of energy for growing infants, as they account for almost 40% of their daily energy intake. In most cow milk-based formulas, lactose is the key source of carbohydrates. Lactose may benefit the gut microbiota and help in the absorption of calcium. According to the EU Directive 2006/141/EC of December 22, 2006, on infant formula and follow-on formula and amending Directive 1999/21/EC, manufacturers shall have a minimum of 9 g of total carbohydrates/100 kcal and a maximum of 14 g/100 kcal.

[INGREDIENTSGRAPH]

According to the U.S. baby infant formula market demand, on the basis of the distribution channel, the hypermarkets segment dominated the market in 2022 and is expected to dominate the market during the forecast period. Hypermarkets significantly invest to improve their supply chain to offer products at the lowest possible (market) relative rate. In addition, these stores invest in categorizing their products and in-store product placement and try to boost the sale of numerous other products while leveraging the sale of one single product.

[DISTRIBUTIONCHANNELGRAPH]

On the basis of the source, the regular segment dominated the market in 2022 accounting for more than one-third of the market share, and is expected to maintain its dominance during the U.S. baby infant formula market forecast period. The highest market share of the regular segment is attributed to the inclination of consumers towards conventional infant formulas, and when it comes to the infant’s health parents are very keen on trusting conventional products over new products as they do not want to take unwanted health risks. Another factor that keeps regular formulas over organic and other formulas is the cost is comparatively cheaper than the organic formulas.

[SOURCEGRAPH]

Players operating in the U.S. baby infant formula market have adopted various developmental strategies to expand their U.S. baby infant formula market share, increase profitability, and remain competitive in the market. Key players profiled in this report include Abbott Laboratories, Arla Foods amba, Aussie Bubs, Bobbie, Danone S.A., Dana Dairy Group Ltd, ByHeart, Else Nutrition Holdings, Inc., Holle Baby Foods AG, Kabrita USA, Nature's One, LLC, Nestle S.A., Reckitt Benckiser Group LTD, and The Hain Celestial Group, Inc.

Some Examples of Agreement in The Market

• In March 2021, Else Nutrition Holdings signed an agreement with United Natural Foods (UNFI) for distribution in over 30,000 retail outlets in the U.S. The agreement will strengthen the presence of the company in the U.S.
• In September 2020, Else Nutrition and KeHE Distributors signed a distribution agreement to bring novel plant-based toddler nutrition product to the U.S. retailers. The agreement will strengthen the presence of the company in local retail stores of the U.S.

Some Examples of Product Launch in The Market

• In January 2021, Bobbie launched first organic, European style infant formula with DHA level that meets the FDA requirements in the U.S. The launch will increase the product portfolio of the company.
• In August 2020 Arla Foods Ingredients launched the organic micellar casein isolate, helping manufacturers meet demand for organic, natural, and functional protein products. Micellar casein isolate is a new ingredient, which is rich in native milk proteins. The launch will increase the product portfolio of the company in the U.S.

KEY BENEFITS FOR STAKEHOLDERS

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the U.S. baby infant formula analysis from 2022 to 2032 to identify the prevailing U.S. baby infant formula opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the U.S. baby infant formula segmentation assists to determine the prevailing market opportunities.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of U.S. baby infant formula industry trends, key players, market segments, application areas, and U.S. baby infant formula Market growth strategies.

 Key Market Segments

• By Product Type
  • Infant milk
  • Follow-on milk
  • Specialty baby milk
  • Growing-up milk
• By Ingredients
  • Carbohydrate
  • Fat
  • Protein
  • Minerals
  • Vitamins
  • Others
• By Distribution Channel
  • Hypermarkets
  • Supermarkets
  • Pharmacy/medical stores
  • Specialty stores
  • Hard discounter stores
  • Others

 
Key Market Players

• Arla Foods Amba
• Bobbie
• Aussie Bubs
• Danone S.A.
• Nature's One, LLC
• Abbott Laboratories
• Else Nutrition Holdings, Inc.
• Holle Baby Foods AG
• The Hain Celestial Group, Inc
• Reckitt Benckiser Group LTD
• ByHeart
• Kabrita USA
• Nestle S.A.
• Dana Dairy Group Ltd

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for the stakeholder
1.3.Key market segments
1.4.Research methodology

1.4.1.Primary Research
1.4.2.Secondary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key finding of the study
2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top investment pockets

3.3.Porter’s five force analysis

3.3.1.Bargaining power of suppliers
3.3.2.Bargaining power of buyers
3.3.3.Threat of new entrants
3.3.4.Threat of substitutes
3.3.5.Intensity of competitive rivalry

3.4.Market dynamics

3.4.1.Drivers

3.4.1.1.Increase in number of women participation in labor force
3.4.1.2.High nutritional content of infant formula

3.4.2.Restraint

3.4.2.1.Concerns related to food safety
3.4.2.2.Government initiatives to promote breastfeeding

3.4.3.Opportunity

3.4.3.1.Shift in preference toward organic baby food & drinks
3.4.3.2.Developments in technology result in emergence of new products
3.4.3.3.Extensive research on prebiotic and probiotics in baby food

3.5.Value chain analysis
3.6.Impact of key regulation
3.7.U.S. Infant Formula Market: COVID-19 Impact Analysis

CHAPTER 4:U.S. BABY INFANT FORMULA MARKET, BY PRODUCT TYPE

4.1.Overview

4.1.1.Market size and forecast

4.2.Infant milk

4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast

4.3.Follow-on milk

4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast

4.4.Specialty baby milk

4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast
4.4.3.Market size and forecast

4.5.Growing-up milk

4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast

CHAPTER 5:U.S. BABY INFANT FORMULA MARKET, BY INGRIDIENT

5.1.Overview

5.1.1.Market size and forecast

5.2.Carbohydrate

5.2.1.Key market trends, growth factors, and opportunities
5.2.2.Market size and forecast

5.3.Fat

5.3.1.Key market trends, growth factors, and opportunities
5.3.2.Market size and forecast

5.4.Protein

5.4.1.Key market trends, growth factors, and opportunities
5.4.2.Market size and forecast

5.5.Minerals

5.5.1.Key market trends, growth factors, and opportunities
5.5.2.Market size and forecast

5.6.Vitamins

5.6.1.Key market trends, growth factors, and opportunities
5.6.2.Market size and forecast

5.7.Others

5.7.1.Key market trends, growth factors, and opportunities
5.7.2.Market size and forecast

CHAPTER 6:U.S. BABY INFANT FORMULA MARKET, BY DISTRIBUTION CHANNEL

6.1.Overview

6.1.1.Market size and forecast

6.2.Hypermarkets

6.2.1.Key market trends, growth factors, and opportunities
6.2.2.Market size and forecast

6.3.Supermarkets

6.3.1.Key market trends, growth factors, and opportunities
6.3.2.Market size and forecast

6.4.Pharmacy/medical stores

6.4.1.Key market trends, growth factors, and opportunities
6.4.2.Market size and forecast

6.5.Specialty stores

6.5.1.Key market trends, growth factors, and opportunities
6.5.2.Market size and forecast

6.6.Hard discounter stores

6.6.1.Key market trends, growth factors, and opportunities
6.6.2.Market size and forecast

6.7.Others

6.7.1.Key market trends, growth factors, and opportunities
6.7.2.Market size and forecast

CHAPTER 7:U.S. BABY INFANT FORMULA MARKET, BY SOURCE

7.1.Overview

7.1.1.Market size and forecast

7.2.Regular

7.2.1.Key market trends, growth factors, and opportunities
7.2.2.Market size and forecast

7.3.Organic

7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Market size and forecast

7.4.Milk with HMO

7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Market size and forecast

7.5.Goat Milk

7.5.1.Key market trends, growth factors, and opportunities
7.5.2.Market size and forecast

7.6.Plant-based formula

7.6.1.Key market trends, growth factors, and opportunities
7.6.2.Market size and forecast

7.7.Others

7.7.1.Key market trends, growth factors, and opportunities
7.7.2.Market size and forecast

CHAPTER 8:COMPETITION LANDSCAPE

8.1.Top winning strategies
8.2.Product mapping
8.3.Competitive dashboard
8.4.Competitive heat map
8.5.Key developments

8.5.1.Acquisition
8.5.2.Business Expansion
8.5.3.Product Launch
8.5.4.Agreement

CHAPTER 9:COMPANY PROFILES

9.1.ABBOTT LABORATORIES

9.1.1.Key Executives
9.1.2.Company snapshot
9.1.3.Operating business segments
9.1.4.Product portfolio
9.1.5.Distribution channel
9.1.6.R&D Expenditure
9.1.7.Business performance

9.2.ARLA FOODS AMBA

9.2.1.Key Executives
9.2.2.Company snapshot
9.2.3.Operating business segments
9.2.4.Product portfolio
9.2.5.Distribution channel
9.2.6.R&D Expenditure
9.2.7.Business performance
9.2.8.Key strategic moves and developments

9.3.AUSSIE BUBS, INC.

9.3.1.Key Executive
9.3.2.Company snapshot
9.3.3.Product portfolio
9.3.4.Distribution channel
9.3.5.Business performance
9.3.6.Key strategic moves and developments

9.4.BOBBIE

9.4.1.Key Executive
9.4.2.Company snapshot
9.4.3.Product portfolio
9.4.4.Distribution channel
9.4.5.Key strategic moves and developments

9.5.DANA DAIRY GROUP LTD.

9.5.1.Company snapshot
9.5.2.Product portfolio
9.5.3.Distribution channel
9.5.4.Key strategic moves and developments

9.6.DANONE SA

9.6.1.Key Executives
9.6.2.Company snapshot
9.6.3.Operating business segments
9.6.4.Product portfolio
9.6.5.Distribution channel
9.6.6.Business performance

9.7.ELSE NUTRITION HOLDINGS INC.

9.7.1.Key Executive
9.7.2.Company snapshot
9.7.3.Product portfolio
9.7.4.Distribution channel
9.7.5.Key strategic moves and developments

9.8.HOLLE BABY FOOD AG

9.8.1.Key Executive
9.8.2.Company snapshot
9.8.3.Product portfolio
9.8.4.Distribution channel

9.9.KABRITA USA

9.9.1.Key Executive
9.9.2.Company snapshot
9.9.3.Product portfolio
9.9.4.Distribution channel

9.10.NATURE’S ONE, LLC

9.10.1.Key Executives
9.10.2.Company snapshot
9.10.3.Product portfolio
9.10.4.Distribution channel
9.10.5.Key strategic moves and developments

9.11.NESTLE S.A.

9.11.1.Key Executives
9.11.2.Company snapshot
9.11.3.Operating business segments
9.11.4.Product portfolio
9.11.5.Distribution channel
9.11.6.R&D Expenditure
9.11.7.Business performance

9.12.RECKITT BENCKISER GROUP PLC

9.12.1.Key Executives
9.12.2.Company snapshot
9.12.3.Operating business segments
9.12.4.Product portfolio
9.12.5.Distribution channel
9.12.6.R&D Expenditure
9.12.7.Business performance

9.13.THE HAIN CELESTIAL GROUP, INC.

9.13.1.Key Executives
9.13.2.Company snapshot
9.13.3.Product portfolio
9.13.4.Distribution channel
9.13.5.Business performance

9.14.BYHEART

9.14.1.Key Executive
9.14.2.Company snapshot
9.14.3.Product portfolio
9.14.4.Distribution channel
 

LIST OF TABLES

TABLE 01.U.S. BABY INFANT FORMULA MARKET VALUE, BY PRODUCT TYPE, 2022–2032 ($MILLION)
TABLE 02.U.S. BABY INFANT FORMULA MARKET VOLUME, BY PRODUCT TYPE, 2022–2032 (KILOTON)
TABLE 03.U.S. BABY INFANT MILK MARKET VALUE, 2022–2032 ($MILLION)
TABLE 04.U.S. BABY INFANT MILK MARKET VOLUME, 2022–2032 (KILOTON)
TABLE 05.U.S. FOLLOW-ON MILK MARKET VALUE, 2022–2032 ($MILLION)
TABLE 06.U.S. FOLLOW-ON MILK MARKET VOLUME , 2022–2032 (KILOTON)
TABLE 07.U.S. SPECIALTY BABY MILK MARKET VALUE, 2022–2032 ($MILLION)
TABLE 08.U.S. SPECIALTY BABY MILK MARKET VOLUME, 2022–2032 (KILOTON)
TABLE 09.U.S. BABY INFANT FORMULA MARKET VALUE, BY POINT OF SALE, 2022–2032 ($MILLION)
TABLE 10.U.S. GROWING-UP MILK MARKET VALUE, 2022–2032 ($MILLION)
TABLE 11.U.S. GROWING-UP MILK MARKET VOLUME, 2020–2030 (KILOTON)
TABLE 12.U.S. BABY INFANT FORMULA MARKET VALUE, BY INGREDIENT, 2022–2032 ($MILLION)
TABLE 13.U.S. BABY INFANT FORMULA MARKET VALUE FOR CARBOHYDRATE, 2022–2032 ($MILLION)
TABLE 14.U.S. BABY INFANT FORMULA MARKET VALUE FOR FAT, 2022–2032 ($MILLION)
TABLE 15.U.S. BABY INFANT FORMULA MARKET VALUE FOR PROTEIN, 2022–2032 ($MILLION)
TABLE 16.U.S. BABY INFANT FORMULA MARKET VALUE FOR MINERALS, 2022–2032 ($MILLION)
TABLE 17.U.S. BABY INFANT FORMULA MARKET VALUE FOR VITAMINS, 2022–2032 ($MILLION)
TABLE 18.U.S. BABY INFANT FORMULA MARKET VALUE FOR OTHERS, 2022–2032 ($MILLION)
TABLE 19.U.S. BABY INFANT FORMULA MARKET VALUE, BY DISTRIBUTION CHANNEL, 2022–2032 ($MILLION)
TABLE 20.U.S. BABY INFANT FORMULA MARKET VALUE FOR HYPERMARKET, 2022–2032 ($MILLION)
TABLE 21.U.S. BABY INFANT FORMULA MARKET VALUE FOR SUPERMARKET, 2022–2032 ($MILLION)
TABLE 22.U.S. BABY INFANT FORMULA MARKET VALUE FOR PHARMACY/MEDICAL STORES, 2022–2032 ($MILLION)
TABLE 23.U.S. BABY INFANT FORMULA MARKET VALUE FOR SPECIALTY STORES, 2022–2032 ($MILLION)
TABLE 24.U.S. BABY INFANT FORMULA MARKET VALUE FOR HARD DISCOUNTER STORES, 2020–2030 ($MILLION)
TABLE 25.U.S. BABY INFANT FORMULA MARKET VALUE FOR OTHERS, 2020–2030 ($MILLION)
TABLE 26.U.S. BABY INFANT FORMULA MARKET VALUE, BY SOURCE, 2022–2032 ($MILLION)
TABLE 27.U.S. BABY INFANT FORMULA MARKET VALUE FOR REGULAR, 2022–2032 ($MILLION)
TABLE 28.U.S. BABY INFANT FORMULA MARKET VALUE FOR ORGANIC, 2022–2032 ($MILLION)
TABLE 29.U.S. BABY INFANT FORMULA MARKET VALUE FOR MILK WITH HMO, 2022–2032 ($MILLION)
TABLE 30.U.S. BABY INFANT FORMULA MARKET VALUE FOR GOAT MILK, 2022–2032 ($MILLION)
TABLE 31.U.S. BABY INFANT FORMULA MARKET VALUE FOR PLANT-BASED FORMULA, 2022–2032 ($MILLION)
TABLE 32.U.S. BABY INFANT FORMULA MARKET VALUE FOR OTHERS, 2022–2032 ($MILLION)
TABLE 33.ABBOTT LABORATORIES: KEY EXECUTIVES
TABLE 34.ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 35.ABBOTT LABORATORIES: OPERATING SEGMENTS
TABLE 36.ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 37.ABBOTT LABORATORIES: DISTRIBUTION CHANNEL
TABLE 38.ABBOTT LABORATORIES: R&D EXPENDITURE, 2020–2022 ($MILLION)
TABLE 39.ABBOTT LABORATORIES: NET SALES, 2020–2022 ($MILLION)
TABLE 40.ARLA FOODS AMBA: KEY EXECUTIVES
TABLE 41.ARLA FOODS AMBA: COMPANY SNAPSHOT
TABLE 42.ARLA FOODS AMBA: OPERATING SEGMENTS
TABLE 43.ARLA FOODS AMBA: PRODUCT PORTFOLIO
TABLE 44.ARLA FOODS AMBA: DISTRIBUTION CHANNEL
TABLE 45.ARLA FOODS AMBA: R&D EXPENDITURE, 2020–2022 ($MILLION)
TABLE 46.ARLA FOODS AMBA: NET SALES, 2020–2022 ($MILLION)
TABLE 47.ARLA FOODS AMBA: ARLA FOODS AMBA
TABLE 48.AUSSIE BUBS, INC.: KEY EXECUTIVE
TABLE 49.AUSSIE BUBS, INC.: COMPANY SNAPSHOT
TABLE 50.AUSSIE BUBS, INC: PRODUCT PORTFOLIO
TABLE 51.AUSSIE BUBS, INC.: DISTRIBUTION CHANNEL
TABLE 52.AUSSIE BUBS, INC.: NET SALES, 2020–2022 ($MILLION)
TABLE 53.AUSSIE BUBS, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 54.BOBBIE: KEY EXECUTIVE
TABLE 55.BOBBIE: COMPANY SNAPSHOT
TABLE 56.BOBBIE: PRODUCT PORTFOLIO
TABLE 57.BOBBIE: DISTRIBUTION CHANNEL
TABLE 58.BOBBIE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 59.DANA DAIRY GROUP LTD: COMPANY SNAPSHOT
TABLE 60.DANA DAIRY GROUP LTD.: PRODUCT PORTFOLIO
TABLE 61.DANA DAIRY GROUP LTD: DISTRIBUTION CHANNEL
TABLE 62.DANA DAIRY GROUP LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 63.DANONE SA: KEY EXECUTIVES
TABLE 64.DANONE SA: COMPANY SNAPSHOT
TABLE 65.DANONE SA: OPERATING SEGMENTS
TABLE 66.DANONE SA: PRODUCT PORTFOLIO
TABLE 67.DANONE SA: DISTRIBUTION CHANNEL
TABLE 68.DANONE SA: NET SALES, 2020–2022 ($MILLION)
TABLE 69.ELSE NUTRITION HOLDINGS INC.: KEY EXECUTIVE
TABLE 70.ELSE NUTRITION HOLDINGS INC.: COMPANY SNAPSHOT
TABLE 71.ELSE NUTRITION HOLDINGS INC.: PRODUCT PORTFOLIO
TABLE 72.ELSE NUTRITION HOLDINGS INC.: DISTRIBUTION CHANNEL
TABLE 73.ELSE NUTRITION HOLDINGS INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 74.HOLLE BABY FOOD AG: KEY EXECUTIVE
TABLE 75.HOLLE BABY FOOD AG: COMPANY SNAPSHOT
TABLE 76.HOLLE BABY FOOD AG: PRODUCT PORTFOLIO
TABLE 77.HOLLE BABY FOOD AG: DISTRIBUTION CHANNEL
TABLE 78.KABRITA USA: KEY EXECUTIVE
TABLE 79.KABRITA USA: COMPANY SNAPSHOT
TABLE 80.KABRITA USA: PRODUCT PORTFOLIO
TABLE 81.KABRITA USA: DISTRIBUTION CHANNEL
TABLE 82.NATURE’S ONE, LLC: KEY EXECUTIVES
TABLE 83.NATURE’S ONE, LLC: COMPANY SNAPSHOT
TABLE 84.NATURE’S ONE, LLC: PRODUCT PORTFOLIO
TABLE 85.NATURE’S ONE, LLC: DISTRIBUTION CHANNEL
TABLE 86.NATURE’S ONE, LLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 87.NESTLE S.A: KEY EXECUTIVES
TABLE 88.NESTLE S.A: COMPANY SNAPSHOT
TABLE 89.NESTLE S.A: OPERATING SEGMENTS
TABLE 90.NESTLE S.A: PRODUCT PORTFOLIO
TABLE 91.NESTLE S.A: DISTRIBUTION CHANNEL
TABLE 92.NESTLE S.A: R&D EXPENDITURE, 2020–2022 ($MILLION)
TABLE 93.NESTLE S.A: NET SALES, 2020–2022 ($MILLION)
TABLE 94.RECKITT BENCKISER GROUP PLC: KEY EXECUTIVES
TABLE 95.RECKITT BENCKISER GROUP PLC: COMPANY SNAPSHOT
TABLE 96.RECKITT BENCKISER GROUP PLC: OPERATING SEGMENTS
TABLE 97.RECKITT BENCKISER GROUP PLC: PRODUCT PORTFOLIO
TABLE 98.RECKITT BENCKISER GROUP PLC: DISTRIBUTION CHANNEL
TABLE 99.RECKITT BENCKISER GROUP PLC: R&D EXPENDITURE, 2020–2022 ($MILLION)
TABLE 100.RECKITT BENCKISER GROUP PLC: NET SALES, 2020–2022 ($MILLION)
TABLE 101.THE HAIN CELESTIAL GROUP, INC: KEY EXECUTIVES
TABLE 102.THE HAIN CELESTIAL GROUP, INC.: COMPANY SNAPSHOT
TABLE 103.THE HAIN CELESTIAL GROUP, INC: PRODUCT PORTFOLIO
TABLE 104.THE HAIN CELESTIAL GROUP, INC.: DISTRIBUTION CHANNEL
TABLE 105.THE HAIN CELESTIAL GROUP, INC: NET SALES, 2020–2022 ($MILLION)
TABLE 106.BYHEART: KEY EXECUTIVE
TABLE 107.BYHEART: COMPANY SNAPSHOT
TABLE 108.BYHEART: PRODUCT PORTFOLIO
TABLE 109.BYHEART: DISTRIBUTION CHANNEL

LIST OF FIGURES

FIGURE 01.KEY MARKET SEGMENTS
FIGURE 02.U.S. BABY INFANT FORMULA MARKET SNAPSHOT, 2022–2032
FIGURE 03.TOP INVESTMENT POCKET, 2022
FIGURE 04.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 05.MODERATE BARGAINING POWER OF BUYERS
FIGURE 06.MODERATE THREAT OF NEW ENTRANTS
FIGURE 07.MODERATE THREAT OF SUBSTITUTES
FIGURE 08.MODERATE INTENSITY OF COMPETITIVE RIVALRY
FIGURE 09.MARKET DYNAMIC ANALYSIS
FIGURE 10.VALUE CHAIN ANALYSIS
FIGURE 11.IMPACT OF KEY REGULATION: U.S. BABY INFANT FORMULA MARKET
FIGURE 12.U.S. BABY INFANT FORMULA MARKET SHARE, BY PRODUCT TYPE, 2022 (%)
FIGURE 13.U.S. BABY INFANT FORMULA MARKET SHARE, BY INGREDIENT, 2022 (%)
FIGURE 14.U.S. BABY INFANT FORMULA MARKET SHARE, BY DISTRIBUTION CHANNEL, 2022 (%)
FIGURE 15.U.S. BABY INFANT FORMULA MARKET SHARE, BY SOURCE, 2022 (%)
FIGURE 16.TOP WINNING STRATEGIES, BY YEAR, 2019–2021*
FIGURE 17.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2019–2021* (%)
FIGURE 18.TOP WINNING STRATEGIES, BY COMPANY, 2019–2021*
FIGURE 19.PRODUCT MAPPING OF TOP 14 KEY PLAYERS
FIGURE 20.COMPETITIVE DASHBOARD OF TOP 14 KEY PLAYERS
FIGURE 21.COMPETITIVE HEATMAP OF TOP 14 KEY PLAYERS
FIGURE 22.ABBOTT LABORATORIES: R&D EXPENDITURE, 2020–2022 ($MILLION)
FIGURE 23.ABBOTT LABORATORIES: NET SALES, 2020–2022 ($MILLION)
FIGURE 24.ABBOTT LABORATORIES: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 25.ABBOTT LABORATORIES: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 26.ARLA FOODS AMBA: R&D EXPENDITURE, 2020–2022 ($MILLION)
FIGURE 27.ARLA FOODS AMBA: NET SALES, 2020–2022 ($MILLION)
FIGURE 28.ARLA FOODS AMBA: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 29.ARLA FOODS AMBA: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 30.AUSSIE BUBS, INC.: NET SALES, 2020–2022 ($MILLION)
FIGURE 31.DANONE SA: NET SALES, 2020–2022 ($MILLION)
FIGURE 32.DANONE SA: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 33.DANONE SA: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 34.NESTLE S.A: R&D EXPENDITURE, 2020–2022 ($MILLION)
FIGURE 35.NESTLE S.A: NET SALES, 2020–2022 ($MILLION)
FIGURE 36.NESTLE S.A: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 37.NESTLE S.A: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 38.RECKITT BENCKISER GROUP PLC: R&D EXPENDITURE, 2020–2022 ($MILLION)
FIGURE 39.RECKITT BENCKISER GROUP PLC: NET SALES, 2020–2022 ($MILLION)
FIGURE 40.RECKITT BENCKISER GROUP PLC: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 41.RECKITT BENCKISER GROUP PLC: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 42.THE HAIN CELESTIAL GROUP, INC: NET SALES, 2020–2022 ($MILLION)
FIGURE 43.THE HAIN CELESTIAL GROUP, INC: REVENUE SHARE BY REGION, 2022 (%)